InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Tuesday, 05/21/2019 11:01:31 AM

Tuesday, May 21, 2019 11:01:31 AM

Post# of 798
News: $ARRY Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer

BOULDER, Colo. , May 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI ® (encorafenib), a BRAF inhibitor, MEKTOVI ® (binimetinib), ...

Read the whole news https://marketwirenews.com/news-releases/array-biopharma-announces-braftovi-mektovi-cetuximab-meet-primary-endpoints-of-orr-and-os-in-phase-3-beacon-crc-trial-interim-analysis-for-the-treatment-of-braf-v600e-mutant-metastatic-colorectal-cancer-8221868.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARRY News